WASHINGTON – In a surprise move that shakes up the Trump administration’s health leadership, Dr. Marty Makary has resigned as Commissioner of the Food and Drug Administration after just 13 months in the role.
President Donald Trump confirmed the departure Tuesday, stating that Makary “was having some difficulty” and that the agency’s deputy commissioner will serve as acting head until a permanent replacement is named.
Makary, a prominent surgeon and Johns Hopkins professor who rose to prominence during the first Trump administration as a vocal critic of certain public health policies, was appointed FDA Commissioner in April 2025. His tenure was marked by internal conflicts, policy clashes with White House advisers, and criticism from multiple sides of the political spectrum.
Sources close to the administration point to several flashpoints that contributed to his exit. These include disagreements over e-cigarette regulations, the pace of drug approvals, and broader tensions regarding agency direction on issues like menopause hormone therapy and psychedelic drug research.
Makary had pushed aggressively to accelerate certain drug review processes and expand access to treatments that aligned with the administration’s priorities. However, his positions on flavored vaping products and other regulatory matters reportedly created friction with key Trump allies and industry stakeholders.
In a brief statement, President Trump said Makary is “a great guy and a wonderful man” but acknowledged the challenges he faced leading the agency. The White House is already searching for a permanent successor, with several names circulating among conservative health policy circles.
Impact on American Healthcare and Consumers
The FDA plays a critical role in approving drugs, overseeing food safety, and regulating medical devices that affect millions of Americans daily. Makary’s sudden departure comes at a time when the agency faces ongoing pressure to balance rapid innovation with rigorous safety standards.
Industry analysts suggest the resignation could lead to a shift in FDA priorities. Possible areas of focus for the next commissioner include faster approvals for new therapies, reforms to the agency’s bureaucracy, and stronger alignment with the current administration’s deregulatory agenda.
Public health experts are watching closely to see who will step into the role. A more industry-friendly leader could accelerate drug approvals but might face pushback from consumer safety advocates. Conversely, a stricter regulator could slow innovation at a time when Americans are demanding quicker access to new treatments.
Background on Dr. Marty Makary
Before joining the FDA, Makary built a reputation as a best-selling author and television commentator. He gained national attention for his critiques of hospital safety, medical errors, and certain aspects of the COVID-19 response. His appointment was seen as a win for those seeking fresh perspectives at the agency.
During his time as commissioner, Makary oversaw several notable initiatives, including efforts to streamline approvals for certain therapies and initiatives supporting expanded research into alternative treatments. However, his leadership style and policy decisions reportedly created divisions within the agency and with external stakeholders.
What Happens Next
The acting commissioner, previously deputy for food policy, will manage day-to-day operations in the interim. The White House has not yet released a shortlist for the permanent position, but insiders expect the next nominee to face intense scrutiny from both Congress and the health policy community.
This development adds to the list of high-profile personnel changes within the Trump administration’s health and regulatory agencies. It also highlights the challenges of leading large federal bureaucracies during a period of significant policy shifts.
Edge World News will continue to follow this story as more details emerge about the reasons behind the resignation and the administration’s plans for the FDA’s future direction. For American families, the leadership of the FDA directly impacts everything from prescription drug costs and availability to the safety of the food supply.
Stay tuned for updates on potential nominees and how this change could affect healthcare policy in the coming months.